BioTuesdays

Category - Markets

Adial Pharma

Maxim starts Adial Pharma at buy; PT $5

Maxim Group initiated coverage of Adial Pharmaceuticals (NASDAQ:ADIL) with a “buy” rating and $5 price target. The stock closed at $1.88 on Oct. 29. Adial is developing AD04, an ultra-low-dose ondansetron therapy for...

Proteon Therapeutics

Maxim starts Proteon Therapeutics at buy; PT $5

Maxim Group launched coverage of Proteon Therapeutics (NASDAQ:PRTO) with a “buy” rating and a price target of $5. The stock closed at $1.71 on Oct. 29. The company’s vonapanitase drug candidate is being evaluated in its...

Celyad Logo

WB starts Celyad at OP; fair market value $53

William Blair launched coverage of Celyad S.A. (NASDAQ:CYAD) with an “outperform” rating and a fair value estimate of $53. The stock closed at $23.58 on Oct.29. Celyad’s lead candidate, CYAD-01, is an autologous...

ADMA Biologics Logo

HCW starts ADMA Biologics at buy; PT $17

H.C. Wainwright initiated coverage of ADMA Biologics (NASDAQ:ADMA) with a “buy” rating and $17 price target. The stock closed at $5.03 on Oct. 29. Since its IPO in 2013, the company’s focus has been on bringing a...

Inspire Medical

Leerink starts Inspire Medical at OP; PT $57

Leerink launched coverage of Inspire Medical Systems (NYSE:INSP) with an “outperform” rating and $57 price target. The stock closed at $40 on Oct. 26. “We see Inspire as a sustainable ultra high-growth/gross margin...

IRIDEX

Stifel starts IRIDEX at buy; PT $9

Stifel initiated coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and price target of $9. The stock closed at $5.40 on Oct. 25. IRIDEX is a leader in developing, manufacturing, and marketing laser-based medical...

Athenex

Ladenburg starts Athenex at buy; PT $27

Ladenburg Thalmann launched coverage of Athenex (NASDAQ:ATNX) with a “buy” rating and $27 price target. The stock closed at $12.37 on Oct. 24. Athenex is focused on the development and commercialization of novel...

Autolus Logo

HCW starts Autolus Therapeutics at buy; PT $45

H.C. Wainwright initiated coverage of Autolus Therapeutics (NASDAQ:AUTL) with a “buy” rating and $45 price target. The stock closed at $30.64 on Oct. 23. Autolus is a UK-based, oncology-focused, autologous cell therapy...

Gritstone Oncology

BTIG starts Gritstone Oncology at buy; PT $26

BTIG launched coverage of Gritstone Oncology (NASDAQ:GRTS) with a “buy” rating and $26 price target. The stock closed at $15.17 on Oct. 22. Gritstone is a clinical-phase oncology company that specializes in focusing a...

IntelGenx Logo

IntelGenx completes $12-million equity offering

IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT)completed an offering of 17,144,314 units at a price of 70 (U.S.) cents each for gross proceeds of approximately $12-million. Each unit consists of one common share of...